Is enzalutamide/enzalutamide a targeted therapy?

Enzalutamide/Enzalutamide (Enzalutamide) is a highly selective androgen receptor inhibitor that is widely used in the treatment of prostate cancer, especially in the field of castration-resistant prostate cancer (CRPC). It has shown important clinical value. Strictly speaking, enzalutamide belongs to the category of endocrine therapy drugs. Its mechanism of action is based on direct targeted antagonism of androgen receptors. Therefore, it can also be regarded as a targeted therapy drug in a broad anti-cancer strategy. It effectively inhibits tumor growth by inhibiting the signal transduction chain of androgen receptors, including blocking the binding of androgens to their receptors, inhibiting the receptors from entering the nucleus, and interfering with the transcriptional activation process after binding to DNA.

Since the development of prostate cancer is closely related to the androgen pathway, enzalutamide demonstrates the "cause intervention" properties of targeted therapy by precisely attacking this critical pathway. In addition, compared with traditional chemotherapy drugs, enzalutamide has better targeting, fewer systemic toxic side effects, and higher oral compliance in the treatment of drug-resistant prostate cancer. This drug is not only suitable for patients with metastatic CRPC, but also shows the advantage of delaying disease progression in the asymptomatic or minimally symptomatic stage. Currently, it has been recommended by multiple national guidelines as one of the first-line standard treatment options for prostate cancer.

Although the targeting characteristics of enzalutamide are relatively concentrated on the androgen pathway, rather than multi-target intervention like some molecular targeted drugs, in clinical practice, its precise mechanism of action and treatment selectivity make it broadly classified as a targeted therapy drug in the field of anti-tumor treatment. In the future, with the advancement of molecular typing and personalized treatment concepts, androgen pathway inhibitors such as enzalutamide will continue to play a key role in the management of prostate cancer, and will also provide an important reference for the refined development of targeted therapy.

Reference materials:https://www.xtandi.com/